Navigation Links
Targeted agent selumetinib shows promise in biliary cancer
Date:4/25/2011

COLUMBUS, Ohio The experimental agent selumetinib has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at The Ohio State University.

Selumetinib, also known as AZD6244 (ARRY-142886), blocks a protein called MEK, which cancer cells need to proliferate and survive.

Biliary cancer is a malignancy of cells lining the bile ducts and gall bladder. About 100,000 patients are diagnosed annually worldwide with the disease, representing 15-20 percent of all liver-cancer cases. Most patients present at later stages of the disease, which has a universally poor outcome.

The findings of this 28-patient, multi-institutional phase II study are reported online in the Journal of Clinical Oncology.

"This malignancy has no good standard of care," says principal investigator Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology and a medical oncologist at Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"Our study provides a strong rationale for developing this agent further in larger trials, probably in combination with other drugs, which we hope will enable us to establish a new standard of care for biliary cancers in the near future," adds Bekaii-Saab.

In addition to Ohio State, trial participants included the University of North Carolina, Vanderbilt University and Emory University.

Selumetinib belongs to a class of drugs called protein-kinase inhibitors. The agent selectively inhibits the protein kinases MEK1 and MEK2. It is part of a signaling pathway that is often damaged in biliary cancer cells. The trial showed the following:

  • One patient responded completely the tumor shrunk until it was undetectable and two patients showed partial tumor shrinkage;
  • In 17 patients, the tumor stopped growing. This condition of stable disease lasted up to 16 weeks in the majority of cases;
  • Patients experienced no cancer progression for a promising 3.7 months on average, despite the fact that nearly 40 percent of patients had prior therapy before receiving selumetinib (such tumors tend to be more resistant to treatment);
  • Patients taking the drug regained weight about 9 pounds on average. This included patients with tumors that may not have responded to the drug, Bekaii-Saab notes.

Patients who lacked a target protein called pERK did not seem to respond to the drug, suggesting that the drug may not work if the protein is missing in the cancer cells. "This finding suggests that in the future we may be able to identify which patients are most likely to respond to the drug," he adds.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Primary care targeted for suicide prevention efforts
2. Modern targeted drug plus old malaria pill serve a 1-2 punch in advanced cancer patients
3. Scientists devise targeted therapy strategy for rare form of childhood cancer
4. Mass. General study reveals how lung cancers evolve in response to targeted treatment
5. New targeted drug helps smokers stub it out
6. Ohio State study: Targeted ovarian cancer therapy not cost-effective
7. VCU Massey first to combine targeted agents to kill multiple myeloma cells
8. IU Personalized Medicine Institute to develop targeted and individualized treatments
9. Targeted particle fools brains guardian to reach tumors
10. PET scans may allow early prediction of response to targeted therapy of thyroid cancer
11. UMMS and Lundbeck to explore potential targeted therapy for Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology: